GWA
IBRX icon

GGM Wealth Advisors’s ImmunityBio IBRX Stock Holding History

GGM Wealth Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$39.7K Buy
+15,105
New +$45.8K 0.02% 134

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

GGM Wealth Advisors's IBRX Position: Q1 2025 in Review

GGM Wealth Advisors opened a new position in ImmunityBio (IBRX) in Q1 2025: 15,105 shares worth $39.7K. The stake represents 0.02% of the portfolio and ranks #134 among its holdings.

211 funds tracked by Wall St. Rank hold IBRX as of Q1 2025.

  • GGM Wealth Advisors held 15,105 shares of ImmunityBio worth $39.7K as of Q1 2025.
  • ImmunityBio was a new GGM Wealth Advisors position in Q1 2025.
  • ImmunityBio made up 0.02% of GGM Wealth Advisors's portfolio in Q1 2025, its #134 holding.
  • 211 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2025.

Based on GGM Wealth Advisors's 13F filing for Q1 2025, filed 1 May 2025.